Landmark trial ONTARGET® proves telmisartan is as protective as ramipril and better tolerated in a broad high-risk cardiovascula

2008-04-14 アップロード · 54 視聴

Results of 25,620 patient study ONTARGET® (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) presented today at the 57th Annual Scientific Session of the American College of Cardiology1

The results of the landmark ONTARGET® Trial have proven that telmisartan, brand name MICARDIS®, a modern angiotensin II receptor blocker (ARB), is as protective as the current gold standard, ramipril, in reducing the risk of cardiovascular death, myocardial infarction, stroke, and hospitalisation for congestive heart failure in a broad cross-section of high-risk cardiovascular patients and with better tolerability.1 These cardiovascular events occurred in 16.66% of patients receiving telmisartan versus 16.46% of patients receiving ramipril.1 The relative risk (ratio of the probability of the event occurring in the telmisartan group versus the ramipril group) was 1.01, with a 95% CI of 0.94 -1.09.

To view Multi-Media News Release, go to http://www.prnewswire.com/mnr/boehringeringelheim/32495/

tag·MICARDIS, ARB, cardiovascular,

非会員の場合は、名前/パスワードを入力してください。

書き込む
今日のアクセス
34
全体アクセス
135,761
チャンネル会員数
35

My Video

リスト形式で表示 碁盤形式で表示

00:36

공유하기
Tanzanite Jewelry is Timeless
8年前 · 30 視聴